Improving Neuropsychiatric Comorbidity in Geriatric Spinocerebellar Ataxia
Objective: This study evaluates neuropsychiatric comorbidity in spinocerebellar ataxia (SCA) and highlights key aspects of management in the geriatric population. It discusses efficacy of neuropsychotropic…eHealth Technologies for People with Parkinson’s: Acceptance & Implications
Objective: To investigate the impact of eHealth on Parkinson's care, focusing on technology acceptance and examining ethical, legal, social, and medical aspects of wearables. Background:…Improvement in Upright Stability subscale of mFARS with Vatiquinone Treatment in MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial
Objective: Describe the results of vatiquinone on the Upright Stability Subscale (USS) from MOVE-FA (NCT04577352), the 72-week placebo-controlled phase 3 study of patients with Friedreich…Reduced intestinal inflammation and increased levels of short-chain fatty acids thanks to an active lifestyle in Parkinson’s disease.
Objective: This study aimed to determine whether people with Parkinson’s disease (PD) with an active lifestyle had increased production of certain microbial metabolites such as…Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON
Objective: The EPSILON study aimed to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa/dopa decarboxylase inhibitor (DDCi) in patients with…Intrinsic Auricular Muscle Zone Stimulation for Moderate-to-Severe Parkinson’s Disease
Objective: To assess the effects of electrical stimulation of the Intrinsic Auricular Muscle Zone (IAMZ) on motor symptoms in patients with moderate-to-severe Parkinson’s disease (PD).…GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation
Objective: To study the potential disease-modifying properties of ambroxol in PD patients with a GBA1 mutation Background: The most common genetic risk factor for Parkinson’s…A Pilot Study of Intrajejunal Faecal Microbiota Transplant to Improve Motor Function in Patients with Parkinson’s Disease Treated with Levodopa-carbidopa Intestinal Gel: Preliminary Findings.
Objective: To determine whether faecal microbiota transplant (FMT) improves motor function in patients with Parkinson Disease (PD) treated with levodopa/carbidopa intestinal gel (LCIG). Background: Preliminary…Long-Term Evolution of Advanced Parkinson’s Disease Burden: Subgroup Analysis from the 24 Month International PROSPECT Observational Study
Objective: To evaluate the long-term evolution of clinical outcomes and treatment patterns in people with advanced Parkinson’s disease (PwaPD) whose symptoms are inadequately controlled by…Meta-Analysis of Two Randomized Controlled Trials Assessing the Efficacy of Mesdopetam (IRL790) in Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To evaluate the efficacy of mesdopetam for the treatment of levodopa-induced dyskinesia in Parkinson’s disease (PD-LID), based on two Phase 2 trials. Background: Mesdopetam…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 181
- Next Page »